Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 6Not yet recruiting 4Recruiting 3Withdrawn 2Terminated 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Thyroid Neoplasms 1Postoperative Complications 1Neoplasms 1Hypothyroidism 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Thyroxine × Clear all
NCT04868045 2023-02-21

Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Withdrawn
Head & Neck

Thyroid Neoplasms

NCT02548715 2022-07-13

LSHT

University of Alberta

Phase 2/3 Withdrawn
Head & Neck

Hypothyroidism, Neoplasms, Postoperative Complications

Data powered by HemOnc (CC BY 4.0) Colophon âš¡